2018 COA Annual Meeting: Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban To Aspirin Following Total Hip And Knee Arthroplasty (EPCAT II)

3424 patients scheduled for or who had undergone either total knee or hip arthroplasty with a 5-day course of rivaroxaban 10mg postoperatively were randomized to extended thromboprophylaxis with either aspirin 81mg daily or continued rivaroxaban 10mg daily. Patients were assessed for the incidence of venous thromboembolism and bleeding events over the first 90 days after surgery, Noninferiority analysis for efficacy demonstrated that extended aspirin was noninferior to extended rivaroxaban. Groups also demonstrated no significant difference in the incidence of bleeding events.